rhTNK-tPA

Phase 3Small molecule

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

rhTNK-tPA is one of 86 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeRecruiting

Acute Ischemic StrokeNot yet recruiting

Ischemic StrokeRecruiting

Cerebrovascular EventRecruiting

StrokePhase 3

Recruiting

Acute Ischemic StrokePhase 3

Not yet recruiting

Ischemic StrokePhase 3

Recruiting

Cerebrovascular EventPhase 3

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

rhTNK-tPA

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Phase 3

3 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cerebrovascular Event

NCT06414499

Q3 2027

Phase 3Recruiting

Ischemic Stroke

NCT07201688

Q1 2028

Phase 3Recruiting

Stroke

NCT06987305

Q3 2029

Phase 3Not yet recruiting

Acute Ischemic Stroke

NCT07748039

Clinical

Trials by Indication[1]

Stroke3 trials

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

Completed·XXinqiao Hospital of Chongqing·Phase 2/3·NCT04733742·550 enrolled

Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

Recruiting·XXinqiao Hospital of Chongqing·Phase 3·NCT06987305·820 enrolled

INtravenous TNK for Acute isChemicsTroke in China

Completed·GGeneral Hospital of Shenyang Military Region··NCT04588337·1,000 enrolled

Cerebrovascular Event2 trials

Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ

Recruiting·—·Phase 3·NCT06414499·1,386 enrolled

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

Completed·—·Phase 3·NCT04797013·1,430 enrolled

Completed·XXuanwu Hospital, Beijing·Phase 4·NCT05752916·570 enrolled

1 more indication

Acute Ischemic Stroke1 trial

Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events (TRACE-BRIDGE): A Multicenter, Randomized, Open-Label, Three-Arm, Blinded-Endpoint Phase III Trial

Not yet recruiting·Yyongjun wang·Phase 3·NCT07748039·1,440 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for rhTNK-tPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhTNK-tPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhTNK-tPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

rhTNK-tPA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Stroke3 trials

Cerebrovascular Event2 trials

Efficacy and Safety1 trial

Ischemic stroke1 trial

Large Vessel Occlusion1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News